We then generated IL-6 transgene-engineered DC (DCIL-6) vaccine by transfection of murine bone marrow (BM)-derived ovalbumin (OVA)-pulsed DCs (DCOVA) with AdVIL-6 and further assessed DCOVA/IL-6-stimulated CTL responses and antitumor immunity in an OVA-specific animal tumor model. This evidence concerns the gene IL6 and neoplasm.